The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

According to Auletta, addressing these disparities requires a collective, ecosystem-wide effort in order to ensure better representation and access for vulnerable patients in stem cell transplants and ...

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients ...

Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...